Brief: Kyowa Kirin Says License Agreement With Synaffix Expanded
30/06/2022 08:07
June 30 (Reuters) - Kyowa Kirin Co Ltd 4151.T :
* KYOWA KIRIN EXPANDS LICENSE AGREEMENT WITH SYNAFFIX AND
TAKES
EXCLUSIVE TARGET RIGHTS BASED ON LATEST POSITIVE ADC DATA
* KYOWA KIRIN - DEAL TRIGGERS $5 MILLION PAYMENT TO SYNAFFIX
&
TOTAL POTENTIAL PAYMENTS FOR 1ST ADC PROGRAM ALONE OF UP TO
$171M PLUS ROYALTIES ON COMMERCIAL SALES
Source text for Eikon: ID:nPreSKQvZa
Further company coverage: 4151.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia